RGTLF (Argent Biopharma) Total Assets: $1.34 Mil (As of Dec. 2025)


What is Argent Biopharma Total Assets?

Argent Biopharma RGTLF Total Assets is $1.34 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Argent Biopharma's Total Assets for the quarter that ended in Dec. 2025 was $1.34 Mil.

During the past 12 months, Argent Biopharma's average Total Assets Growth Rate was -79.50% per year. During the past 3 years, the average Total Assets Growth Rate was -59.50% per year. During the past 5 years, the average Total Assets Growth Rate was -26.20% per year. During the past 10 years, the average Total Assets Growth Rate was 0.70% per year.

During the past 13 years, Argent Biopharma's highest 3-Year average Total Assets Growth Rate was 475.50%. The lowest was -80.50%. And the median was 16.90%.

Total Assets is connected with ROA %. Argent Biopharma's annualized ROA % for the quarter that ended in Dec. 2025 was -265.04%. Total Assets is also linked to Revenue through Asset Turnover. Argent Biopharma's Asset Turnover for the quarter that ended in Dec. 2025 was 0.08.

Argent Biopharma  (OTCPK:RGTLF) Total Assets Explanation

Total Assets is connected with ROA %.

Argent Biopharma's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-3.9/( (1.607+1.336)/ 2 )
=-3.9/1.4715
=-265.04 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Argent Biopharma's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0.114/( (1.607+1.336)/ 2 )
=0.114/1.4715
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Argent Biopharma Total Assets Related Terms

Argent Biopharma Total Assets Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Total Assets Chart

Argent Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.53 16.55 6.63 7.16 1.61

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.60 7.16 1.94 1.61 1.34

Argent Biopharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Argent Biopharma's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=-5.618+7.225
=1.61

Argent Biopharma's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=-5.611+6.947
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $1.34 Mil mean?
Argent Biopharma (RGTLF) has a Total Assets of $1.34 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Argent Biopharma and its competitors.
Is Argent Biopharma's Total Assets too high?
Argent Biopharma's current Total Assets is $1.34 Mil.
How does Argent Biopharma's Total Assets compare to ZTS and UTHR?
Argent Biopharma's Total Assets of $1.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Argent Biopharma and its competitors. Argent Biopharma's current Total Assets is $1.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Total Assets is $1.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Total Assets is $1.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.